



(51) International Patent Classification:

A61K 31/7125 (2006.01)

(21) International Application Number:

PCT/US2018/050248

(22) International Filing Date:

10 September 2018 (10.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/556,818 11 September 2017 (11.09.2017) US
 62/643,927 16 March 2018 (16.03.2018) US
 62/720,434 21 August 2018 (21.08.2018) US

(71) Applicant: **ARROWHEAD PHARMACEUTICALS, INC.** [US/US]; 225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 (US).(72) Inventors: **LI, Zhen**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **ZHU, Rui**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **PEI, Tao**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US). **KANNER, Steven**; Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 (US). **WONG, So**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).(74) Agent: **TEIGEN, Robert, Michael**; Arrowhead Pharmaceuticals, Inc., 502 S. Rosa Road, Madison, WI 53719 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
 — with sequence listing part of description (Rule 5.2(a))

(54) Title: RNAI AGENTS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF APOLIPOPROTEIN C-III (APOC3)

(57) Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents *in vivo* provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.



PCT

(PCT Rule 92*bis*.1 and
Administrative Instructions, Section 422)

TEIGEN, Robert, Michael
Arrowhead Pharmaceuticals, Inc.
502 S. Rosa Road
Madison, WI 53719
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (<i>day/month/year</i>) 29 November 2019 (29.11.2019)	
Applicant's or agent's file reference 30655-WO1	IMPORTANT NOTIFICATION
International application No. PCT/US2018/050248	International filing date (<i>day/month/year</i>) 10 September 2018 (10.09.2018)

1. The following indications appeared on record concerning: ☒ the applicant ☐ the inventor ☐ the agent ☐ the common representative			
Name and Address ARROWHEAD PHARMACEUTICALS, INC. 225 South Lake Avenue, Suite 1050 Pasadena, CA 91101 United States of America		State of Nationality	State of Residence
		US	US
		Telephone No. 1-626-304-3400	
		Facsimile No. 1-626-304-3401	
		E-mail address patents@arrowheadpharma.com	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning: ☐ the person ☐ the name ☒ the address ☐ the nationality ☐ the residence			
Name and Address ARROWHEAD PHARMACEUTICALS, INC. 177 East Colorado Boulevard, Suite 700 Pasadena, CA 91105 United States of America		State of Nationality	State of Residence
		US	US
		Telephone No. 1-626-304-3400	
		Facsimile No. 1-626-304-3401	
		E-mail address patents@arrowheadpharma.com ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:			
4. A copy of this notification has been sent to: ☒ the receiving Office ☐ the International Searching Authority ☐ the Authority(ies) specified for supplementary search ☐ the International Preliminary Examining Authority ☒ the designated Offices concerned ☐ the elected Offices concerned ☐ other:			

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Dezempte Anne e-mail pct.team6@wipo.int Telephone No. +41 22 338 74 06
--	---

From the INTERNATIONAL BUREAU

PCTNOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

TEIGEN, Robert, Michael
Arrowhead Pharmaceuticals, Inc.
502 S. Rosa Road
Madison, WI 53719
ÉTATS-UNIS D'AMÉRIQUE

Date of mailing (day/month/year) 10 January 2020 (10.01.2020)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 30655-WO1	
International application No. PCT/US2018/050248	International filing date (day/month/year) 10 September 2018 (10.09.2018)

1. The following indications appeared on record concerning:		
☐ the applicant	☒ the inventor	☐ the agent
☐ the common representative		
Name and Address ZHU, Rui Arrowhead Pharmaceuticals, Inc. 502 S. Rosa Road Madison, WI 53719 United States of America	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
☐ the person	☐ the name	☒ the address
☐ the nationality		
☐ the residence		
Name and Address ZHU, Rui 9427 Stonewood Blvd. Middleton, WI 53562 United States of America	State of Nationality	State of Residence
	Telephone No.	
	Facsimile No.	
	E-mail address ☐ Notifications by e-mail authorized	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
☒ the receiving Office	☐ the International Preliminary Examining Authority	
☐ the International Searching Authority	☒ the designated Offices concerned	
☐ the Authority(ies) specified for supplementary search	☐ the elected Offices concerned	
	☐ other:	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer Moussaid El Mostafa e-mail pct.team6@wipo.int Telephone No. +41 22 338 74 06
---	---